Group 1 - The stock of Haocen Medical reached a closing price of 3.56 yuan on August 12, with a limit-up performance and a closing order fund of 89.68 million yuan, accounting for 3.0% of its market capitalization [1] - The growth in the oral medical business is significant, with Delun Medical's sales revenue expected to increase by 13.94% year-on-year in 2024, indicating a strong expansion trend [1] - The company has improved its operational efficiency, with net profit losses narrowing by 60.06% year-on-year in 2024, signaling positive developments [1] Group 2 - Research and development expenses are projected to surge by 163% year-on-year in Q1 2025, reinforcing the company's strategic investments to enhance long-term competitiveness [1] - A new outpatient clinic in Zhaoqing is set to open in May 2025, along with the expansion of several medical facilities, increasing the number of dental chairs by over 100, thereby enhancing service capacity [1] - The company secured a 113.2 million yuan working capital loan, alleviating short-term financial pressures [1]